As far as some synthetic agonists of GPR55 were recently described to induce cell death in breast cancer cells [37], it could be worthwhile testing whether the LPI cytotoxicity enhancement also takes place for other GPR55 ligands or is specific to the NADA class. This evidence concerns the gene GPR55 and breast carcinoma.